UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Use of Citrated Whole Blood for Point-of-Care Viscoelastic Coagulation Testing in Dogs

Frontiers in veterinary science, 2022-03, Vol.9, p.827350-827350

2022

Volltextzugriff (PDF)

Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial

Gynecologic oncology, 2024-08, Vol.187, p.128-138

2024

Volltextzugriff (PDF)

Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012

Gynecologic oncology, 2024-10, Vol.189, p.68-74

2024

Volltextzugriff (PDF)

Detecting schizophrenia early: Prediagnosis healthcare utilization characteristics of patients with schizophrenia may aid early detection

Schizophrenia research, 2020-01, Vol.215, p.392-398

2020

Volltextzugriff (PDF)

Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions

International journal of gynecological cancer, 2023-11, Vol.33 (11), p.1733-1742

2023

Volltextzugriff (PDF)

Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment

Current medical research and opinion, 2018-06, Vol.34 (6), p.995-1003

2018

Volltextzugriff (PDF)

Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study

International journal of gynecological cancer, 2024-07, Vol.34 (7), p.1041-1050

2024

Volltextzugriff (PDF)

Predictors of long-term progression-free survival (PFS) in niraparib-treated patients (pts) from the PRIMA/ENGOT-OV26/GOG-3012 study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5589-5589

2023

Volltextzugriff (PDF)

EP233/#541 Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease following first-line chemotherapy: PRIMA/ENGOT-ov26/GOG-3012 post-hoc subgroup analysis

International journal of gynecological cancer, 2022-12, Vol.32 (Suppl 3), p.A144-A144

2022

Volltextzugriff (PDF)

EP224/#531 Optimization of assessment of disease progression between blinded central independent review and investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial

International journal of gynecological cancer, 2022-12, Vol.32 (Suppl 3), p.A140-A141

2022

Volltextzugriff (PDF)

A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Clinical cancer research, 2021-10, Vol.27 (19), p.5248-5257

2021

Volltextzugriff (PDF)

Efficacy of a community‐based participatory and multilevel intervention to enhance hepatitis B virus screening and vaccination in underserved Korean Americans

Cancer, 2018-03, Vol.124 (5), p.973-982

2018

Volltextzugriff (PDF)

Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor

Journal of clinical oncology, 2024-04, Vol.42 (11), p.1301-1310

2024

Volltextzugriff (PDF)

1.37 Is Use of Psychotherapy Associated With Lower Need for Psychotropic Polypharmacy Among Medicaid Children?

Journal of the American Academy of Child and Adolescent Psychiatry, 2017-10, Vol.56 (10), p.S164-S165

2017

Volltextzugriff (PDF)

Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy

European journal of cancer (1990), 2024-09, Vol.208, p.114157, Article 114157

2024

Volltextzugriff (PDF)

Health Care Resource Utilization and Cost Before Initial Schizophrenia Diagnosis

Journal of managed care & specialty pharmacy, 2019-10, Vol.25 (10), p.1102-1110

2019

Volltextzugriff (PDF)

F214. Health Care Resource Utilization is Higher in Patients Prior to Diagnosis With Schizophrenia Than Non-Schizophrenia Comparators in a Large Commercially Insured Population in the United States

Biological psychiatry (1969), 2018-05, Vol.83 (9), p.S322-S322

2018

Volltextzugriff (PDF)

Rate of preventative vaccine use and vaccine beliefs among a commercially insured population

Vaccine, 2020-10, Vol.38 (45), p.7087-7093

2020

Volltextzugriff (PDF)

Niraparib treatment for patients with BRCA -mutated ovarian cancer: review of clinical data and therapeutic context

Future oncology (London, England), 2022-07, Vol.18 (23), p.2505-2536

2022

Volltextzugriff (PDF)

S252. HEALTH CARE RESOURCE UTILISATION IS HIGHER IN PATIENTS PRIOR TO DIAGNOSIS WITH SCHIZOPHRENIA THAN NON-SCHIZOPHRENIA COMPARATORS IN A LARGE COMMERCIALLY-INSURED POPULATION IN THE UNITED STATES

Schizophrenia bulletin, 2018-04, Vol.44 (suppl_1), p.S425-S426

2018

Volltextzugriff (PDF)

Health Care Resource Utilization and Cost Before Initial Schizophrenia Diagnosis

Journal of managed care & specialty pharmacy, 2019-07, p.1-10

2019

Volltextzugriff (PDF)

4.47 Patient Characteristics and Patterns of Care Prior to Schizophrenia Diagnosis in a Large Commercially-Insured Population of Adolescents and Young Adults in the United States

Journal of the American Academy of Child and Adolescent Psychiatry, 2017-10, Vol.56 (10), p.S244-S245

2017

Volltextzugriff (PDF)

556 Tolerability of the niraparib individualised starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy

International journal of gynecological cancer, 2024-03, Vol.34 (Suppl 1), p.A580-A581

2024

Volltextzugriff (PDF)

2022-RA-1505-ESGO Ovarian cancer retrospective European (O’CaRE) observational study: analysis of first-line (1L) outcomes in patients with ovarian cancer (OC) stratified by number of risk factors for progression

International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A344-A344

2022

Volltextzugriff (PDF)

Efficacy of a Community-Based Participatory and Multilevel Intervention to Enhance Hepatitis B Screening and Vaccination in Underserved Korean Americans

Cancer, 2017-11, Vol.124 (5), p.973-982

2017

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(40)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(57)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Use of Citrated Whole Blood for Point-of-Care Viscoelastic Coagulation Testing in Dogs

Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial

Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012

Detecting schizophrenia early: Prediagnosis healthcare utilization characteristics of patients with schizophrenia may aid early detection

Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions

Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment

Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study

Predictors of long-term progression-free survival (PFS) in niraparib-treated patients (pts) from the PRIMA/ENGOT-OV26/GOG-3012 study

EP233/#541 Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease following first-line chemotherapy: PRIMA/ENGOT-ov26/GOG-3012 post-hoc subgroup analysis

EP224/#531 Optimization of assessment of disease progression between blinded central independent review and investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial

A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Efficacy of a community‐based participatory and multilevel intervention to enhance hepatitis B virus screening and vaccination in underserved Korean Americans

Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor

1.37 Is Use of Psychotherapy Associated With Lower Need for Psychotropic Polypharmacy Among Medicaid Children?

Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy

Health Care Resource Utilization and Cost Before Initial Schizophrenia Diagnosis

F214. Health Care Resource Utilization is Higher in Patients Prior to Diagnosis With Schizophrenia Than Non-Schizophrenia Comparators in a Large Commercially Insured Population in the United States

Rate of preventative vaccine use and vaccine beliefs among a commercially insured population

Niraparib treatment for patients with BRCA -mutated ovarian cancer: review of clinical data and therapeutic context

S252. HEALTH CARE RESOURCE UTILISATION IS HIGHER IN PATIENTS PRIOR TO DIAGNOSIS WITH SCHIZOPHRENIA THAN NON-SCHIZOPHRENIA COMPARATORS IN A LARGE COMMERCIALLY-INSURED POPULATION IN THE UNITED STATES

Health Care Resource Utilization and Cost Before Initial Schizophrenia Diagnosis

4.47 Patient Characteristics and Patterns of Care Prior to Schizophrenia Diagnosis in a Large Commercially-Insured Population of Adolescents and Young Adults in the United States

556 Tolerability of the niraparib individualised starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy

2022-RA-1505-ESGO Ovarian cancer retrospective European (O’CaRE) observational study: analysis of first-line (1L) outcomes in patients with ovarian cancer (OC) stratified by number of risk factors for progression

Efficacy of a Community-Based Participatory and Multilevel Intervention to Enhance Hepatitis B Screening and Vaccination in Underserved Korean Americans

Suchergebnisse filtern